Overview

Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This is a funded implementation study designed to evaluate the efficacy of recruiting and retaining high-risk individuals on pre-exposure prophylaxis (PrEP) within multiple private pharmacies (and online platforms in South Africa)
Phase:
PHASE4
Details
Lead Sponsor:
Professor Francois Venter
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Emtricitabine
Lamivudine
Racivir
Tenofovir